PCM
RUBY

Penserra Capital Management’s Rubius Therapeutics, Inc RUBY Stock Holding History

Penserra Capital Management’s Portfolio RUBY Stock Details RUBY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2,060
Closed -$36K – 1620
2021
Q3 		$36K Buy
2,060
+25
+1% +$544 ﹤0.01% 1147
2021
Q2 		$49K Buy
2,035
+200
+11% +$5K ﹤0.01% 1006
2021
Q1 		$48K Sell
1,835
-20
-1% -$292 ﹤0.01% 821
2020
Q4 		$14K Buy
1,855
+1,165
+169% +$6.92K ﹤0.01% 894
2020
Q3 		$3K Buy
+690
New +$3.65K ﹤0.01% 896

Other funds holding RUBY

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Penserra Capital Management's RUBY Position: Q4 2021 in Review

Penserra Capital Management sold out of Rubius Therapeutics, Inc (RUBY) in Q4 2021, closing a stake of 2,060 shares — an estimated $36K sold.

Penserra Capital Management first reported a position in RUBY in Q3 2020 and held it in 5 quarters. The position peaked at $49K in Q2 2021. 108 funds tracked by Wall St. Rank hold RUBY as of Q4 2021.

  • Penserra Capital Management reported no remaining Rubius Therapeutics, Inc position as of Q4 2021 after selling out during the quarter.
  • Penserra Capital Management sold 2,060 Rubius Therapeutics, Inc shares in Q4 2021, an estimated $36K.
  • Penserra Capital Management first reported a position in Rubius Therapeutics, Inc in Q3 2020 and held it in 5 quarters.
  • Penserra Capital Management's Rubius Therapeutics, Inc position peaked at $49K in Q2 2021.
  • 108 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q4 2021.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.